Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation : I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021
(2023) In Eurosurveillance 28(47).- Abstract
Introduction: Two large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients≥20 years, combining data from these networks during Alpha (March–June)- and Delta (June–December)dominant periods, 2021. Methods: Forty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case–control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine≥14 days before onset. Results: We included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the... (More)
Introduction: Two large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients≥20 years, combining data from these networks during Alpha (March–June)- and Delta (June–December)dominant periods, 2021. Methods: Forty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case–control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine≥14 days before onset. Results: We included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARSCoV2 for complete Comirnaty PSV was 85% (95% CI: 69–92) overall and 75% (95% CI: 42–90) in those aged≥80 years. During the Delta period, among SARI patients≥20 years with symptom onset≥150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18–74). Among those receiving Comirnaty PSV and mRNA booster (any product)≥150 days after last PSV dose, VE was 91% (95% CI: 57–98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose < 90 days before onset; ≥ 70% in those 90–179 days before onset. Conclusions: Our results from this EU multi-country hospital setting showed that VE for complete PSV alone was higher in the Alpha-than the Delta-dominant period, and addition of a first booster dose during the latter period increased VE to over 90%.
(Less)
- author
- Rose, Angela M.C. and Kissling, Esther
- contributor
- Gefenaitė, Giedrė
LU
- author collaboration
- organization
- publishing date
- 2023-11-23
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Eurosurveillance
- volume
- 28
- issue
- 47
- article number
- 2300186
- publisher
- European Centre for Disease Prevention and Control (ECDC)
- external identifiers
-
- scopus:85177867806
- pmid:37997666
- ISSN
- 1025-496X
- DOI
- 10.2807/1560-7917.ES.2023.28.47.2300186
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © 2023 European Centre for Disease Prevention and Control (ECDC). All rights reserved.
- id
- ae92bbcc-9f2a-4aff-b37d-fd7603623dec
- date added to LUP
- 2025-11-19 15:14:15
- date last changed
- 2025-11-20 03:26:37
@article{ae92bbcc-9f2a-4aff-b37d-fd7603623dec,
abstract = {{<p>Introduction: Two large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients≥20 years, combining data from these networks during Alpha (March–June)- and Delta (June–December)dominant periods, 2021. Methods: Forty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case–control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine≥14 days before onset. Results: We included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARSCoV2 for complete Comirnaty PSV was 85% (95% CI: 69–92) overall and 75% (95% CI: 42–90) in those aged≥80 years. During the Delta period, among SARI patients≥20 years with symptom onset≥150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18–74). Among those receiving Comirnaty PSV and mRNA booster (any product)≥150 days after last PSV dose, VE was 91% (95% CI: 57–98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose < 90 days before onset; ≥ 70% in those 90–179 days before onset. Conclusions: Our results from this EU multi-country hospital setting showed that VE for complete PSV alone was higher in the Alpha-than the Delta-dominant period, and addition of a first booster dose during the latter period increased VE to over 90%.</p>}},
author = {{Rose, Angela M.C. and Kissling, Esther}},
issn = {{1025-496X}},
language = {{eng}},
month = {{11}},
number = {{47}},
publisher = {{European Centre for Disease Prevention and Control (ECDC)}},
series = {{Eurosurveillance}},
title = {{Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation : I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021}},
url = {{http://dx.doi.org/10.2807/1560-7917.ES.2023.28.47.2300186}},
doi = {{10.2807/1560-7917.ES.2023.28.47.2300186}},
volume = {{28}},
year = {{2023}},
}